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Abstract
Background: A core outcome set (COS) represents the agreed minimum set of domains and measurement
instruments that should be measured and reported in any clinical trial for a given condition. In BMS randomized
controlled trials (RCTs), the outcomes identified in the existing literature regarding the efficacy of therapeutic
interventions are numerous and diverse. Although the standardized IMMPACT core outcome domains has been
developed for measurement of outcomes in chronic pain RCTs, no BMS-specific COS have been adopted and
validated. With the evolving landscape of BMS management end points and the development of new therapies, a
consensus on a COS for use in future BMS trials is paramount to reduce heterogeneity in outcome reporting. The
aim of this study was to reach a consensus for adopting the standardized Initiative on Methods, Measurement, and
Pain Assessment in Clinical Trials (IMMPACT) outcome domains, and their tools of assessment, for burning mouth
syndrome (BMS) clinical trials and clinical practice.
Methods: A BMS-specific COS will be developed using the method recommended by the Core Outcome Measures in
Effective Trials (COMET) initiative (Registration: http://www.comet-initiative.org/studies/details/1357). Selection of
questionnaire outcome measures was informed by the IMMPACT consensus and previous systematic review of RCTs in
BMS conducted by the consortium. An international group of clinicians and researchers will be invited to participate in
several rounds of a Delphi survey. A consensus meeting will be held with the objective of ratifying the outcomes for
inclusion in the COS. A finalized COS explanatory document will be drafted, including all outcomes and measurements
as determined by the Delphi rounds and consensus meeting.
Discussion: A COS for the management of BMS will improve the quality of future RCTs, reduce outcome reporting
heterogeneity, and facilitate more vigorous data synthesis of management interventions for systematic reviews and
meta-analysis. This would ensure enhanced quality evidence for clinical management of the condition.
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Introduction
Randomized controlled trials (RCTs) represent the gold
standard for generating evidence on the efficacy of clin-
ical interventions and should incorporate clearly defined
outcome measures. The outcome measures identified in
published RCTs concerning the efficacy of therapeutic
interventions in burning mouth syndrome (BMS) are
numerous and inconsistent [1]. To date, no BMS-
specific outcome measures exist. BMS is a unique syn-
drome as occasionally not only pain is experienced, but
often other dysesthesias including dry mouth and dys-
geusia exist, symptoms currently not captured on exist-
ing outcome measures. Also, as BMS affects the oral
cavity, it requires certain core outcome domains includ-
ing functioning (for example, avoidance of food types,
frequency of dietary-related discomfort) to be taken this
into consideration which could potentially be useful
measures of improvement separate to pain. The Initia-
tive on Methods, Measurement, and Pain Assessment in
Clinical Trials (IMMPACT) is an expert consensus strat-
egy that provides a set of recommended core outcome
domains to be considered when conducting RCTs con-
cerning interventions for chronic pain and includes: pain
dimension, physical functioning, emotional functioning,
participant’s ratings of global improvement, symptoms
and adverse events, and participant’s disposition [2, 3].
This set of outcome domains recommended for chronic
pain is highly applicable for BMS and can be adopted
when conducting BMS RCTs to ensure consistency and
homogeneity across RCTs in assessing management out-
comes. A recent systematic review explored the report-
ing of IMMPACT outcome measures in all BMS RCTs,
published after 1994, and identified a paucity of studies
reporting on these standardized measures. Poor
utilization of accepted outcome measures may limit
transparency, impact the interpretation of treatment ef-
fects and, subsequently, could create inaccurate
evidence-based healthcare decisions [4]. In addition, it
limits the ability to compare findings between RCTs and
synthesize data for meta-analyses. The ideal core out-
come set (COS) should cover biological, psychological,
and social aspects affected by chronic pain [5].
The Core Outcome Measures in Effective Trials
(COMET) (http://www.comet-initiative.org/) initiative,
funded by the MRC North West Hub for Trials Method-
ology (NWHTMR) and launched in 2010, addresses the
problem of heterogeneity in RCT outcome measures by
developing a guideline for the creation of a COS [6]. A
COS represents the agreed minimum set of domains
and measurement instruments that should be measured
and reported in any clinical trial for a given condition to
ensure comparable outcome assessment [7]. With the
evolving landscape of BMS management end points and
the development of new therapies, a consensus
agreement on a COS for use in future BMS trials, based
on the existing IMMPACT core outcomes, is of vital im-
portance. The Delphi method, which uses a series of se-
quential questionnaires sent to participants who are
chosen for their expertise in their field, has been used in
multiple studies with the aim of developing a COS when
no consensus or guidelines exist [8–10].
It is expected that the COS will always be collected
and reported, but is not so restrictive in negating clini-
cians and researchers from exploring additional out-
comes. Implementation of a successful COS in BMS
RCTs will provide a minimum outcome-reporting stand-
ard and should reduce heterogeneity in reporting find-
ings. Reducing heterogeneity in outcome reporting will
overcome the limitations in the interpretability of results
and enable integration of data in systematic reviews and
meta-analyses.
To the best of our knowledge, no studies have been
conducted to develop consensus on the minimum COS
that should be measured and reported in BMS RCTs.
Consequently, this study aims to describe the protocol
for developing, and reaching expert consensus, for a
COS that can be recommended for inclusion in future
clinical trials on BMS management strategies.
Methods
A systematic literature review has previously been con-
ducted to identify potential efficacy and safety outcomes
currently reported in BMS RCTs (i.e., IMMPACT out-
come domains) [1]. A search of the COMET initiative
database (http://www.comet-initiative.org/) was com-
pleted prior to commencing this project. No published
or ongoing COS for BMS trials was identified. A Delphi
method [11] will be used by an international steering
group with the intention of developing a COS, based on
the existing IMMPACT outcome domains, for future
RCTs concerning the management of BMS. The pub-
lished recommendations for the development of an
international consensus BMS-specific COS using the
Delphi technique and checklist will be followed [12, 13].
The study protocol was checked via the COS-STAP
(Core Outcome Set-STAndardised Protocol Items) [14]
checklist (Additional file 1).
Several consecutive rounds of online questionnaires to
generate consensus on the BMS COS will be conducted
involving researchers and clinicians, with broad geo-
graphical representation, using a three-round Delphi
survey, with additional rounds if needed. The anonymity
of the Delphi method allows panel members to derive
consensus and gives equal weight to all participants,
avoids prominent personalities from dictating the con-
sensus, and facilitates international involvement [11].
After each round (iteration), the group responses are
provided to participants who can then reconsider their
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decision in light of other viewpoints. Identification of
additional outcomes important to clinicians with a spe-
cial interest in BMS will take place by using free re-
sponse options in the survey rounds. The COS will be
ratified in a consensus meeting of global experts. This
COS has been listed in the non-database list of the
COMET initiative (http://www.comet-initiative.org/stud-
ies/details/1357).
Scope of the BMS COS
This COS is intended as the international standard for
clinical trials examining the efficacy of management strat-
egies in adult patients (≥ 18 years) with a clinically defined
diagnosis of burning mouth syndrome in accordance with
recognized diagnostic criteria such as The International
Classification of Orofacial Pain (ICOP) or the Inter-
national Headache Society (IHS), who will undergo an
interventional therapeutic trial in an attempt to manage
their oral burning symptoms.
Objectives
1. To develop a list of BMS reported outcomes based
on the IMMPACT recommendations, for use in a
Delphi survey
2. To develop a consensus on a preliminary BMS-COS
and their tools of assessment using the outcomes
collated from objective 1, via a 3-round Delphi
survey.
3. Using the preliminary COS, develop a final COS,
and their tools of assessment, for use in future BMS
RCTs and in clinical practice.
4. Disseminate and promote the implementation of
the COS to key stakeholders internationally.
Stakeholder involvement
Outcomes measured, and their tools of assessments, in
clinical trials must be meaningful to healthcare profes-
sionals, researchers, and patients to ensure its accept-
ance and its implementation. In this project, we will
conduct surveys, with both qualitative and quantitative
responses, with clinicians and researchers in the field of
BMS with the following aims:
1. Consensus on outcome measures generated
through the IMMPACT recommendations as
reported in the recently published systematic review
[3].
2. Expansion of this list with items considered
important but not captured in the systematic
review.
3. Reaching consensus regarding what tools of
assessment should be utilized in BMS RCTs for
those IMMPACT domains where multiple tools of
assessment were recommended.
Inclusion criteria for participants
 Age ≥ 25 years old
 Ability to read and write in English
 Hold a post-graduate qualification (MS, DMD, DDS,
PhD, or equivalent)
 Access to online surveys
 Provided ≥ 5 years clinical care and/or research in
BMS.
Sample size for participants
There is currently no published COS for measuring/
monitoring facial pain in trials and clinical practice,
though a COS for trigeminal neuralgia is currently in de-
velopment (http://www.comet-initiative.org/studies/de-
tails/1123). Other studies have used 9 to 678 (median
110) participants in their protocol to develop a COS [9,
15–18]. Consequently, with a sample size of 40 to 50, we
will reach an adequate representative sample. No sample
power calculation is required for this study for two rea-
sons: (1) the lack of previous studies in this specific topic
and (2) the goal is to see a pattern in answers and reach
expert agreement, rather than statistical significance.
Dissemination of the survey
Questionnaires will be electronically sent to clinicians/re-
searchers who specialize in oral medicine, orofacial pain,
and/or clinical psychology who assess BMS patients. This
will include members of oral medicine and orofacial pain
societies, such as the European Association of Oral Medi-
cine, British and Irish Society of Oral Medicine, American
Academy of Oral Medicine, American Academy of Orofa-
cial Pain, The Oral Medicine Academy of Australia, Aus-
tralian and New Zealand Academy of Orofacial Pain, and
International Association for the Study of Pain. List-serves
will be utilized. This allows for a global range of clinical
experiences and geographical expertise. Purposive sam-
pling also will be undertaken to identify and prioritize indi-
viduals who have published in the field of BMS in the last
15 years. All potential participants will be contacted with
an invitation letter outlining the aims and details of the
study and the rationale and importance of completing the
Delphi approach, along with an invitation to take part via
a link to Qualtrics® (https://exchange.tufts.edu/owa/redir.
aspx?C=n_lkhDqjBVtUSGmKSH9aT2s1RhsMTaCmbAM
_rGV6pLk1WiXgVdrXCA..&URL=https%3a%2f%2ftufts.
qualtrics.com%2fjfe%2fform%2fSV_3sn85hA3IIYZxqZ).
For each round of the process, participants will have 14
days to complete the survey with e-mail reminders sent
out four days before closure. Participants will be masked
to the other respondents in the study.
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Data handling
We anticipate an 80% response rate to reach our goal of
having at least 32–40 participants in each round. Drop-
outs of the study will not be counted during the round
which they drop-out. However, their responses from
previous rounds will be analyzed. Data will be exported
to an Excel spreadsheet for qualitative and quantitative
data analysis. NVivo software will be used for qualitative
free text data analysis and coding of themes. Data will be
secured in encrypted and password protected files. In-
ductive coding will be used to code open-ended re-
sponses in each survey round [19]. A code book to
analyze free response data will be developed by reading
line-by-line responses from 10 participants and explicit
definitions and rules for applying the code will be cre-
ated; additional codes will be added if needed [19, 20].
Each transcript will be independently coded by two
members of the research team to allow for inter-coder
reliability (ICR) assessment of agreement throughout the
coding process. ICR will be calculated using the Kappa
statistic, and members of the research team will meet to
resolve discrepancies when a code’s Kappa is less than
0.5 and percent agreement is less than 80% [21].
Ethical approval and funding
Ethical approval has been obtained from Tufts School of
Dental Medicine Boston, Massachusetts (IRB ID:
STUDY00000329). There is no funding obtained for this
project. Informed consent will be obtained at the start of
each round by a tick box stating “I consent, begin the
study.” Identifying information will not be collected dur-
ing the consenting process.
Detailed method for each Delphi round
Delphi round one
We anticipate the Delphi process will consist of three
rounds of electronic-based questionnaires conducted be-
tween May and December 2020. Background informa-
tion on the rationale of the development of the COS will
be provided. Respondents will initially be asked to indi-
cate the stakeholder group to which they belong and
complete questions regarding their professional back-
ground and clinical or research experience relevant to
BMS. The list of outcomes generated from the system-
atic review will be formatted into questions with a 5-
point Likert scale, from “strongly agree” to “strongly dis-
agree,” to identify outcomes of importance to experts
[22]. The first round will include close-ended and open-
ended questions. Prior to sending the questionnaires,
they will be pilot tested by a small group of clinicians
not involved in the study to ensure clarify. Patients will
be involved in the development and review of the ques-
tionnaires used in this study prior to distribution to
study participants.
Consensus is pre-defined as at least 80% of the respon-
dents being in agreement (Table 1) [8, 9, 18, 23]. Agree-
ment is defined as a response of “agree” or “strongly
agree” for a given item. If consensus is reached in any of
the rounds, then those items will be omitted from rating
in the subsequent round. Items that reach consensus in
round 1 will be brought forward for round 2 only if
there are suggested changes so that they can be rated
again in the context of new suggestions.
The initial items to be used for round 1 were based on
IMMPACT consensus outcome domains as specified in
the recent systematic review conducted by our group to
identify reported outcomes in BMS RCTs. Forty-six
items will be included in round 1. Through free text
entry, respondents will have the option to clarify opin-
ions for and against inclusion of outcomes and to pro-
vide additional suggestions on other relevant clinical
outcomes not included in the round 1 questionnaire.
Round 1 will allow the steering group to assess the fre-
quency and mode of the scores of all respondents and
use this as a measure of agreement. A large spread is as-
sociated with a weaker consensus. Data analysis from
round 1 and creation of the subsequent questionnaire
for the next round will take place 2 weeks after the re-
sponse due date. Responses from round 1 will be ana-
lyzed by descriptive statistics to summarize the number
of participants scoring each outcome and the distribu-
tion of scores in a feedback report. Any new clinical out-
comes identified from free text responses will be added
to Delphi round 2. Non-respondents of the round 1 sur-
vey will not be invited to participate in round 2.
Delphi round two
Round 2 will be a close-ended questionnaire, with one
or two open-ended questions if needed. In round 2, each
participant will be provided with the number of respon-
dents and distribution of scores for each outcome gener-
ated from round 1. Participants will then be asked to
rescore each outcome in light of the group responses.
Each outcome will be re-scored on a 5-point Likert scale
as previously described. Participants may choose to
change their score or not. Changes in score from round-
Table 1 Definitions of consensus
Consensus
classification
Description Definition
Consensus
in
Outcome should be
included in the COS
> 80% respondents scoring as 4
or 5 AND < 15% scoring as 1 or
2
Consensus
out
Outcome should be
excluded from the
COS
50% or fewer scoring 4 or 5 in
each stakeholder group
No
consensus
Uncertainty regarding
importance of
outcome
Anything else
Carey et al. Trials          (2020) 21:711 Page 4 of 6
to-round will be documented. Responses from round 2
will be analyzed using descriptive statistics. Participants
will also be asked to score any new clinical outcomes
identified in round 1. Participants will have the oppor-
tunity for a free response item if they would like to pro-
vide additional opinions.
Delphi round three
Similar to round 2, round 3 will be a close-ended ques-
tionnaire. A feedback report of items which reached con-
sensus, response rate, and frequency and mode of
responses will be provided to participants. Each outcome
that failed to reach consensus in the previous rounds will
be presented and re-scored on a 5-point Likert scale. If
consensus is reached, the new COS for BMS RCTs will
then be presented as a group for voting. If consensus is
reached on additional outcomes, they will be added and
the final COS proposed will be presented for final voting.
Outcomes not meeting the definitions of inclusion and ex-
clusion, as discussed above, will be classified as lack of
consensus. Study participants will also be asked to provide
feedback on the results of the Delphi method.
Consensus meeting
If consensus has not been reached after the 3-round Del-
phi or there is significant disagreement, a consensus
meeting will be held with the objective of ratifying the
outcomes for inclusion in the COS. The results from
each round of the Delphi survey will be reviewed and
participants will approve the outcomes that meet con-
sensus criteria for inclusion and exclusion. Participants
also will discuss the outcomes where there was lack of
agreement. Outcomes where there was a lack of consen-
sus during the Delphi process will be discussed and par-
ticipants will anonymously vote for each outcome for
inclusion and exclusion in the finalized COS. At the
conclusion of the process, we should have identified
what COS should be measured in clinical trials for BMS.
Discussion
This protocol paper describes the multi-step process
that will be used to develop a COS for BMS. At the time
of writing, there is no published COS for BMS. A COS
for the management of BMS will help improve the de-
sign, conduct, and reporting of future RCTs, with re-
duced outcome reporting bias and heterogeneity
between studies. This will enhance the comparability of
studies and allow pooling of data for meta-analyses. A fi-
nalized COS reporting guideline and explanatory docu-
ment will be drafted as determined by the Delphi rounds
and consensus meeting. These documents will be dis-
seminated by high-impact publication and through rele-
vant international meetings. The outcomes included will
be relevant to a range of stakeholders including patients,
healthcare professionals, researchers, and healthcare pol-
icy decision-makers.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04640-4.
Additional file 1. Core Outcome Set-STAndardised Protocol Items: the
COSSTAP Statement.
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